Analysts expect Achaogen Inc (NASDAQ:AKAO) to post ($0.96) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Achaogen’s earnings, with the lowest EPS estimate coming in at ($1.20) and the highest estimate coming in at ($0.72). Achaogen posted earnings of ($0.85) per share during the same quarter last year, which suggests a negative year over year growth rate of 12.9%. The business is scheduled to report its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Achaogen will report full year earnings of ($3.93) per share for the current year, with EPS estimates ranging from ($4.20) to ($3.56). For the next financial year, analysts anticipate that the business will report earnings of ($2.37) per share, with EPS estimates ranging from ($3.22) to ($1.80). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Achaogen.
Achaogen (NASDAQ:AKAO) last released its quarterly earnings data on Monday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.19). Achaogen had a negative net margin of 2,286.21% and a negative return on equity of 146.50%. The company had revenue of $2.56 million for the quarter, compared to analysts’ expectations of $1.49 million.
Several equities analysts recently weighed in on AKAO shares. Stifel Nicolaus lifted their price target on Achaogen from $14.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, August 7th. Cowen restated a “buy” rating on shares of Achaogen in a research note on Friday, July 27th. SunTrust Banks cut their price target on Achaogen from $16.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, August 20th. BidaskClub upgraded Achaogen from a “hold” rating to a “buy” rating in a research note on Monday, June 18th. Finally, lifted their price target on Achaogen to $2.54 and gave the company a “sell” rating in a research note on Tuesday, July 3rd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. Achaogen has a consensus rating of “Hold” and a consensus target price of $18.95.
A number of hedge funds have recently bought and sold shares of AKAO. DekaBank Deutsche Girozentrale acquired a new stake in Achaogen in the 1st quarter worth about $207,000. Swiss National Bank boosted its holdings in Achaogen by 12.9% in the 1st quarter. Swiss National Bank now owns 50,000 shares of the biopharmaceutical company’s stock worth $648,000 after buying an additional 5,700 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Achaogen by 16.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 160,830 shares of the biopharmaceutical company’s stock worth $2,083,000 after buying an additional 23,114 shares during the last quarter. Engineers Gate Manager LP boosted its holdings in Achaogen by 154.8% in the 1st quarter. Engineers Gate Manager LP now owns 97,817 shares of the biopharmaceutical company’s stock worth $1,267,000 after buying an additional 59,422 shares during the last quarter. Finally, BlackRock Inc. boosted its holdings in Achaogen by 2.1% in the 1st quarter. BlackRock Inc. now owns 2,898,459 shares of the biopharmaceutical company’s stock worth $37,536,000 after buying an additional 60,613 shares during the last quarter. Institutional investors own 60.61% of the company’s stock.
Shares of Achaogen stock opened at $4.31 on Tuesday. The company has a current ratio of 3.79, a quick ratio of 3.79 and a debt-to-equity ratio of 0.42. Achaogen has a twelve month low of $4.06 and a twelve month high of $16.49.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Read More: Exchange-Traded Funds (ETFs)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.